Tag Archives: Europe

Industry Takes EU to Task Over Pharmacovigilance Fees

Europe’s leading pharma industry bodies — EFPIA, EGA, EuropaBio, AESGP and EUCOPE — have issued a joint statement to express concern about “the increasing financial burden of regulatory costs incurred since the adoption of the pharmacovigilance package in 2010″.  Procedural fees such as for pharmacovigilance referrals, they argue, have been significantly increased in the last […]
Posted in Europe, Global, Regulatory | Also tagged , , , , , , | Leave a comment

HTAs Impact on Biosimilars in Europe

Cuts in healthcare costs due to post-recession austerity programs mean favorable Health Technology Assessments (HTAs) are becoming crucial to the successful market launch of pharmaceuticals in Europe. HTAs backing reimbursement can be vital for new innovative medicines and also for biosimilars. EUnetHTA has been stepping up its efforts to achieve more consistency in the methodology […]
Posted in Europe, Regulatory | Also tagged , , , , | Leave a comment

How Good for UK Pharma is the European Union?

As the United Kingdom debate about whether to stay in the European Union becomes more bitter and intense, an insight into how EU membership impacts on medicines and pharmaceuticals has appeared from a British politician who was until recently the UK Government Adviser on Life Sciences, George Freeman. His view—which is less than rosy—is worth […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , | 1 Comment

Type 2 Diabetes Opportunities in Europe "Vast", Says Report

“Vast” Diabetes Opportunities in Europe, Says Report The European type 2 diabetes market earned revenues of €9.50 billion in 2009 and is estimated to reach €15.46 billion in 2017 (CAGR 3.8 percent), according to new research by Frost & Sullivan. The International Diabetes Federation states that more than 55 million people have been diagnosed with […]
Posted in Europe, healthcare | Also tagged , , , , , , , | Leave a comment

The EMA Turns 20: What Does It Want to Be?

Reflector looks at the growing pains of the European Medicine Agency (EMA) as it faces the key policy challenges of 2014. The European Medicines Agency (EMA) is 20 years old this year — and it confronts many of the problems familiar to anyone at that age. After the vigorous growth and boundless optimism of its […]
Posted in Europe, Global, Regulatory | Also tagged , , , , | Leave a comment
  • Categories

  • Meta